Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
MNKD
MannKind Corporation
NASDAQGM
Biotechnology
United States
$4.08
▲
+0.11 (+2.90%)
OPEN
—
OPEN
$3.92
HIGH
$4.10
LOW
$3.92
PREV CLOSE
$3.96
VOLUME
1.87M
0.42x avg
BID / ASK
2.93 / 5.03
spr 2.100
MARKET CAP
$1.31B
DAY RANGE
$3.92
$4.10
P/E (TTM)
—
Fwd 32.0
EPS (TTM)
-0.15
DIV YIELD
—
52W HIGH
$6.51
-37.4%
52W LOW
$2.23
+82.7%
BETA
1.10
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
PRE-MARKET
$3.92
-0.04
(-1.01%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
MNKD
$4.08
▲
+2.90%
Chart
Valuation
Financials
Peers
News
MNKD · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-OFF
253 BARS · -23.7% YOY
1-year price chart. Started at 5.34, currently 4.07, down 23.7 percent. Range 2.28 to 6.21 over 253 data points.
2025-09-04
$5.34 → $4.07 (-23.7%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
RISK-OFF
DCF FV $0.81 · -80.0% VS SPOT
DCF Fair Value
$0.81
DCF vs Spot
-80.0%
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· DCF $0.81 (-80.0%)
Peers:
CGEM
REPL
ODTX
ORIC
MGTX PE16
JBIO
JANX
CRVS
FINANCIALS
Multi-Year Financials (SEC XBRL)
RISK-ON
YOY REV +22.2% · 3 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$349.0M
$5.9M
$18.3M
$13.7M
$792.2M
2024-12
$285.5M
$27.6M
$42.5M
$32.8M
$393.8M
2023-12
$199.0M
-$11.9M
$34.1M
-$8.3M
$475.2M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
CGEM
REPL
ODTX
ORIC
MGTX
JBIO
JANX
CRVS
GLUE
KURA
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
MannKind to Present at Upcoming Investor Conferences
GlobeNewswire · 2026-09-02
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
Simply Wall St. · 2026-08-29
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
Zacks · 2026-08-28
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
MT Newswires · 2026-08-06
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
Zacks · 2026-08-06
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
GuruFocus.com · 2026-08-06
MannKind Q2 Earnings Call Highlights
MarketBeat · 2026-08-06
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
Zacks · 2026-08-05